Enalare Therapeutics Appoints Herm Cukier as Executive Chairman, President, and CEO

Enalare Therapeutics Inc., a clinical stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from acute respiratory conditions, announced today that it has appointed biopharma industry veteran Herm Cukier as its Executive Chairman of the Board, President, and Chief Executive Officer.

Enalare Therapeutics Inc., a clinical stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from acute respiratory conditions, announced today that it has appointed biopharma industry veteran Herm Cukier as its Executive Chairman of the Board, President, and CEO. ​

Herm brings extensive and diverse industry experience to Enalare spanning nearly three decades, including leading efforts to develop and launch a multitude of novel breakthrough therapies across several therapeutic categories. In addition, his past successes in building high performing organizations, driving transformative commercial results, and building significant shareholder value will be instrumental in helping Enalare to achieve its ambition of becoming a leading biopharmaceutical enterprise.

“We are very excited to have someone of Herm’s experience and abilities lead our Company as we prepare to initiate pivotal studies for our proprietary and novel compound ENA-001, a potassium channel inhibitor proven in human studies to be an effective and safe agnostic respiratory stimulant,” stated co-founder and Chief Research and Development Officer, Joe Pergolizzi.

“I am honored to join the Enalare team,” stated Herm Cukier. “We are experiencing unprecedented simultaneous national health emergencies in acute respiratory depression. With ENA-001 and our other products, we have the potential to bring significant relief to these patients. I look forward to working with my colleagues in developing and bringing these innovative solutions to market.”

Mr. Cukier was most recently the CEO and Member of the Board of Directors at BioDelivery Sciences, leading its transformation into a rapidly growing and profitable organization. During his tenure, the company accomplished many important milestones including eight straight quarters of record level performance, expanding its portfolio, and improving its capital position through a very successful equity offering and debt restructuring.

Prior to joining BDSI Herm was a Senior Vice President at Allergan, leading both its largest and fastest growing billion dollar divisions in Eye Care and Women’s Health, as well as leading the creation of the company’s progressive Digital Ventures Group while being head of Strategy and Innovation. He was a member of both the Global Commercial Leadership and CEO Operational Leadership Teams.

Herm has also held a series senior leadership positions with other top tier pharmaceutical companies including Bayer and Bristol Myers Squibb. He was the Chief Marketing Officer and member of the management team at Organon Biosciences where he served as the commercial spokesperson for the company’s IPO before being acquired by Schering-Plough. Mr. Cukier received his MBA in Marketing from the Columbia Business School and a BSE in Bioengineering from The University of Pennsylvania.

About Enalare Therapeutics Inc.

Enalare Therapeutics Inc. is a clinical stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from acute respiratory conditions, including respiratory depression caused by drug overdose, post-surgery, and COVID-19. The Company is planning to initiate pivotal studies in the US for its lead compound ENA-001.

Contact:
Morgan Wagner
Investor Relations
mwagner@enalare.com

Source: Enalare Therapeutics Inc.